Safety Protocols Checklist: What to Look for Before Getting an Online Ketamine Prescription

Why Safety Protocols Matter in Telehealth Ketamine

Ketamine is a powerful medication with real therapeutic benefits and real risks. When administered in a clinic under direct medical supervision, many safety concerns are managed in real time by trained staff with emergency equipment on hand. Telehealth ketamine — where patients take the medication at home — removes that layer of in-person oversight, which makes the safety protocols surrounding the program critically important.

The safety protocols a telehealth ketamine provider follows are not just bureaucratic formalities. They are the systems that stand between you and preventable adverse events. Before getting an online ketamine prescription, you should understand what safety protocols should be in place and verify that your chosen provider actually implements them.

This article provides a detailed checklist you can use to evaluate any telehealth ketamine program.

Pre-Treatment Safety Protocols

Comprehensive Psychiatric Evaluation

The foundation of safe ketamine prescribing is a thorough psychiatric evaluation conducted by a licensed clinician via live video consultation. This evaluation should cover:

• Current symptoms and diagnosis: The clinician should assess your current mental health symptoms using standardized tools (such as the PHQ-9 for depression or the PCL-5 for PTSD)
• Treatment history: A review of what treatments you have tried previously, including medications, therapy, and other interventions
• Substance use history: Honest assessment of current and past substance use, including alcohol, cannabis, opioids, and stimulants
• Psychiatric history: Previous diagnoses, hospitalizations, suicide attempts, and psychotic episodes
• Family psychiatric history: Relevant family history, particularly of psychotic disorders or substance use disorders

A proper evaluation takes time. If your initial consultation lasts fewer than 20 minutes, the provider may not be conducting adequate screening. For more warning signs, see our red flags guide.

Medical History and Contraindication Screening

Ketamine has specific medical contraindications that must be screened before prescribing. A safe program will ask about and document:

• Cardiovascular conditions: Uncontrolled hypertension, unstable angina, recent myocardial infarction, aortic aneurysm, or other conditions where ketamine's sympathomimetic effects (increased heart rate and blood pressure) pose a risk
• Hepatic function: Ketamine is metabolized by the liver; significant liver disease may affect metabolism and increase risk
• Pregnancy and breastfeeding: Ketamine is contraindicated during pregnancy
• Urinary tract conditions: Chronic ketamine use is associated with ketamine-induced cystitis; pre-existing lower urinary tract symptoms should be assessed
• Intracranial pressure: Conditions involving elevated intracranial pressure are a contraindication
• Active psychosis or mania: Active psychotic symptoms or manic episodes are contraindications for ketamine therapy
• Glaucoma: Ketamine can increase intraocular pressure

Medication Interaction Review

A safe program conducts a thorough medication review because ketamine interacts with several drug classes:

• Benzodiazepines: May blunt ketamine's therapeutic effects and complicate sedation management
• MAOIs: Potential for dangerous interactions including hypertensive crisis
• Lithium: Risk of prolonged ketamine effects
• CNS depressants: Additive sedation risk with opioids, barbiturates, and other sedating medications
• Lamotrigine: Some evidence of interaction that may affect ketamine response

The prescriber should know every medication and supplement you take. If a provider does not ask for a complete medication list, that is a protocol failure. Our contraindications guide details all drug interactions and medical exclusions.

Baseline Vital Signs

Before initiating treatment, safe programs require documentation of baseline vital signs, particularly blood pressure and heart rate. Some programs require you to purchase a blood pressure cuff and report readings. Others accept recent readings from your primary care provider.

This baseline serves two purposes: screening out patients with uncontrolled hypertension and establishing a reference point for monitoring during treatment.

Informed Consent

Informed consent for ketamine therapy should be a thorough document — not a checkbox. It should clearly explain:

• The off-label nature of sublingual ketamine (only Spravato/esketamine nasal spray has specific FDA approval for treatment-resistant depression; sublingual ketamine is prescribed off-label)
• Expected effects during a session, including dissociation, altered perception, and potential anxiety
• Common side effects: nausea, dizziness, elevated blood pressure, drowsiness
• Serious risks: cardiovascular events, psychological distress, misuse potential, urinary tract effects with prolonged use
• What to do in an emergency
• The provider's protocol for adverse events
• Conditions under which treatment will be discontinued

Read this document carefully. If it is vague, incomplete, or absent, reconsider the provider.

During-Treatment Safety Protocols

Session Sitter Requirement

Most responsible telehealth ketamine programs require that a sober adult be physically present during your ketamine sessions, particularly during initial treatments. This sitter serves as a safety monitor who can:

• Call emergency services if needed
• Prevent falls or physical injury during dissociative states
• Provide reassurance if you experience anxiety or distress
• Monitor for signs of adverse reactions

A program that does not require a session sitter — especially for initial doses — is accepting unnecessary risk. Some programs relax this requirement after several successful sessions at a stable dose, which is a reasonable clinical judgment.

Vital Sign Monitoring During Sessions

Safe programs require blood pressure and heart rate monitoring before and during sessions. A typical protocol involves:

1. Taking a pre-session blood pressure reading
2. Proceeding only if readings are within acceptable parameters (usually below 160/100 mmHg, though specific thresholds vary by provider)
3. Taking a reading during or after the session
4. Reporting readings to the clinical team

Ketamine causes transient increases in blood pressure and heart rate. Monitoring catches the small percentage of patients who experience clinically significant elevations that require intervention.

Environmental Safety Instructions

A thorough safety protocol includes guidance on preparing your environment:

• Remove tripping hazards from the treatment area
• Have a comfortable, safe place to lie down
• Keep a bucket or bag nearby in case of nausea
• Ensure a phone is accessible for the sitter to call for help
• Do not lock doors that emergency responders might need to access
• Have water available
• Ensure the session will not be interrupted by children, pets, or other disruptions

Nothing by Mouth (NPO) Guidelines

Because ketamine can cause nausea and because aspiration is a risk during sedation, safe programs provide fasting instructions — typically no food for 4-6 hours before the session and no liquids for 2 hours before.

Emergency Protocol

Every safe telehealth ketamine program should have a clearly documented emergency protocol that covers:

• What symptoms require calling 911 immediately (severe chest pain, difficulty breathing, loss of consciousness, seizure)
• What symptoms should be reported to the clinical team urgently (severe nausea, sustained elevated blood pressure, prolonged dissociation, extreme anxiety)
• A clinical on-call number for after-hours emergencies
• Instructions for the session sitter on how to position an unconscious patient and what information to give paramedics

If a provider cannot articulate their emergency protocol when asked, they have not adequately prepared for adverse events.

Post-Session and Ongoing Safety Protocols

Post-Session Restrictions

Safe programs clearly communicate post-session restrictions:

• No driving for at least 12-24 hours after a session
• No operating heavy machinery for the same period
• No alcohol on the day of treatment
• No major decisions (legal, financial, relationship) in the hours following a session, as judgment may be temporarily impaired
• No bathing or showering unsupervised until fully recovered, due to drowning risk

Follow-Up Appointments

Regular follow-up with the prescribing clinician is a non-negotiable safety protocol. Follow-ups should assess:

• Treatment response (using standardized measures, not just "how do you feel?")
• Side effects and tolerability
• Any signs of developing dependence or misuse
• Whether dose adjustments are needed
• Whether continued treatment is appropriate

The frequency of follow-ups varies, but monthly check-ins at minimum are standard. Providers that prescribe ketamine indefinitely without regular reassessment are not following safe practice.

Dose Titration Protocol

Safe programs start at conservative doses and titrate based on individual response. A typical approach:

• Start at a low dose for the first 1-2 sessions
• Assess tolerability and response
• Increase gradually if needed
• Establish the minimum effective dose rather than the maximum tolerable dose

Programs that start all patients at the same dose regardless of body weight, age, medical history, and concurrent medications are not individualizing care adequately.

Monitoring for Misuse

Legitimate programs monitor for signs of ketamine misuse, including:

• Requests for dose increases without clinical justification
• Requests for early refills
• Reports of using ketamine outside of the prescribed protocol
• Running out of medication before the refill date
• Signs of psychological dependence

Some programs use prescription drug monitoring programs (PDMPs) to check for concurrent controlled substance prescriptions. This cross-checking is an important safeguard.

Periodic Reassessment for Continuation

Safe programs periodically reassess whether continued ketamine treatment is appropriate. Not every patient should remain on ketamine indefinitely. Reassessment should consider:

• Whether treatment goals have been met
• Whether the benefits continue to outweigh the risks
• Whether urinary tract symptoms have developed (a concern with long-term use)
• Whether liver function should be checked (for patients on extended treatment)
• Whether a taper or discontinuation trial is appropriate

Your Pre-Commitment Checklist

Use this checklist before committing to any telehealth ketamine provider. A safe program should meet all of these criteria:

Pre-treatment:

• Live video evaluation with a licensed prescriber (not just a questionnaire)
• Comprehensive psychiatric and medical history
• Complete medication review
• Baseline vital sign documentation
• Thorough informed consent covering risks, benefits, and off-label status
• Clear contraindication screening

During treatment:

• Session sitter required (at least for initial sessions)
• Vital sign monitoring protocol
• Environmental safety instructions provided
• Fasting guidelines provided
• Documented emergency protocol with on-call clinical support

Ongoing care:

• Regular follow-up appointments with the prescriber
• Standardized outcome tracking
• Dose titration based on individual response
• Monitoring for misuse indicators
• Periodic reassessment of treatment continuation

If a provider meets all of these criteria, they are following the safety protocols that the clinical community recognizes as standard for at-home ketamine therapy. If they are missing multiple items from this checklist, consider finding a provider with more rigorous safety standards.

The Bottom Line

The safety protocols a telehealth ketamine program follows determine whether your treatment experience will be safe and well-managed or unnecessarily risky. These protocols exist because ketamine, while genuinely effective for many patients, carries real cardiovascular, psychological, and misuse risks that require active management.

Before getting an online ketamine prescription, ask direct questions about every item on this checklist. The provider's willingness to answer — and the quality of their answers — will tell you a great deal about how seriously they take patient safety.

References

• Sanacora G, et al. (2017). A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 74(4), 399-405 — Expert consensus on clinical safety standards for ketamine therapy
• FDA Drug Safety Communication — Esketamine (Spravato) — FDA safety requirements and REMS program for esketamine
• DEA — Scheduling of Ketamine — DEA classification and regulatory requirements for ketamine
• Krystal JH, et al. (2019). Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron, 101(5), 774-778 — Overview of ketamine's therapeutic mechanism and safety considerations
• American Psychiatric Association — APA Statement on Ketamine — Professional guidance on appropriate clinical use
• NIH National Institute of Mental Health — Ketamine Research — Federal research on ketamine safety and efficacy